EFMC-Yearbook-2020

Recommendations

Info

Advisory BoardThe Advisory Board is an EFMC consulting body for the Executive Committee, assisting in assessing the Federation’s strategicgoals. The tasks of the AB consist of:→ advising on EFMC policy related matters internally and externally→ proposing novel scientific or political initiatives to the Executive Committee→ proposing strategies on how to increase awareness of Medicinal Chemistry and support the community in Europe→ proposing strategies on how to affect and interact with stakeholders in EuropeThe AB is composed of eminent scientists in life sciences and medicinal chemistry and is chaired by the Past President.The EFMC is thankful to all of them for their dedication and valuable contribution.CURRENT BOARD MEMBERSHIPProf. Koen AUGUSTYNS - AB ChairUniversity of Antwerp, BelgiumProf. Maria Laura BOLOGNESIUniversity of Bologna, ItalyDr Karin BRINERNovartis, United StatesProf. François DIEDERICHETH Zürich, SwitzerlandDr Anette GRAVEN SAMSLundbeck, DenmarkProf. Herbert WALDMANNMax Planck Institute of Molecular Physiology, GermanyDr Tony WOODGlaxoSmithKline, United KingdomTo see the previous composition of the Advisory Board, please click here8 | EFMC YEARBOOK 2020
Influencing EU-PolicyThe EU-Policy working group aims to highlight the role ofMedicinal Chemistry as a key player for addressing globalhealth issues, as well as to position the EFMC as anexpert organisation in the discipline.At the Basel Workshop in February 2019, we sought topinpoint strategic mechanisms for influencing EU Policy.Two specific goals were identified:→To increase visibility, awareness and funding ofMedicinal Chemistry→To identify and recommend lobbying strategies at theEU, regional and national levelsTo achieve these goals in the short term a paper/executivesummary will be written based upon two previousEU level workshops organized by EFMC togetherwith EuChemS: a STOA initiative on “Solving AntibioticResistance” and a workshop on “Cause and Cure forParkinson’s Disease” were organized in 2015 and 2018, respectively.Using this executive summary, contacts at theEU Parliament, Commission and/or Council will be approachedin order to establish robust, strategic relationshipsbetween the EFMC and these organisations. In thelong term, the group will identify and define emergingtopics within the discipline and organize focused meetingsin the parliament. We will continue to interact notonly with EuChemS but also with other key stakeholdersin the Life Science area, e.g., EUFEPS. Consolidating influenceover regional policies and national contact pointsvia EFMC Council members will also be a focus. In addition,EU officers will be invited to participate at roundtable discussions related to research policy at EFMC conferences.CURRENT MEMBERSHIPAnders KARLÉN (chair)Uppsala University, SwedenPhil JONESEuropean Screening Centre Newhouse,University of Dundee, UKPeter SJÖDrugs for Neglected Diseases initiative (DNDi),SwitzerlandFranz VON NUSSBAUMBayer AG, GermanyDuring the year, the EFMC EU Policy group has alsoworked with EUFEPS, EuChemS and other stakeholdersto start a forum for the exchange of ideas and joint futureactivities at the European level.9
Page 1 and 2: YEARBOOK 2020Medicinal Chemistry in
Page 3 and 4: ContentEditorial 2Corporate Members
Page 5 and 6: pants is gratefully acknowledged. Y
Page 7 and 8: EFMC Executive CommitteeThe EFMC Ex
Page 9: Prof. Anders KARLÉN(Uppsala Univer
Page 13 and 14: Best Practices in Medicinal Chemist
Page 15 and 16: MEET THE TEAMKristina GONCHARENKO S
Page 17 and 18: EFMC-ACSMEDI MedChem Frontiers 2019
Page 19: 12 3WINNING PICTURES1 Inverted Natu
Page 23 and 24: To acknowledge and recognize an out
Page 25 and 26: 7 th EFMC Young Medicinal Chemist S
Page 27 and 28: 16th EFMC Short Courseon Medicinal

EFMC-Yearbook-2020

Create successful ePaper yourself

Delete template?

Save as template?